The Metabolic Profile of Tumors Depends on Both the Responsible Genetic Lesion and Tissue Type

Mariia O. Yuneva,1,* Teresa W.M. Fan,4 Thaddeus D. Allen,1 Richard M. Higashi,4 Dana V. Ferraris,5 Takashi Tsukamoto,5,6 José M. Matés,7 Francisco J. Alonso,7 Chunmei Wang,2 Youngho Seo,3 Xin Chen,2 and J. Michael Bishop1

1G.W. Hooper Research Foundation
2Department of Bioengineering and Therapeutic Sciences
3Department of Radiology and Biomedical Imaging
University of California, San Francisco, San Francisco, CA 94143, USA
4Center for Regulatory and Environmental Analytical Metabolomics, Department of Chemistry, University of Louisville, Louisville, KY 40208, USA
5Brain Science Institute
6Department of Neurology
Johns Hopkins University, Baltimore, MD 21205, USA
7Department of Molecular Biology and Biochemistry, Faculty of Sciences, University of Málaga, 29071 Málaga, Spain
*Correspondence: mariia.yuneva@ucsf.edu

SUMMARY

The altered metabolism of tumors has been considered a target for anticancer therapy. However, the relationship between distinct tumor-initiating lesions and anomalies of tumor metabolism in vivo has not been addressed. We report that MYC-induced mouse liver tumors significantly increase both glucose and glutamine catabolism, whereas MET-induced liver tumors use glucose to produce glutamine. Increased glutamine catabolism in MYC-induced liver tumors is associated with decreased levels of glutamine synthetase (Glul) and the switch from Gls2 to Gls1 glutaminase. In contrast to liver tumors, MYC-induced lung tumors display increased expression of both Glul and Gls1 and accumulate glutamine. We also show that inhibition of Gls1 kills cells that overexpress MYC and catabolize glutamine. Our results suggest that the metabolic profiles of tumors are likely to depend on both the genotype and tissue of origin and have implications regarding the design of therapies targeting tumor metabolism.

INTRODUCTION

Increased consumption and altered metabolism of two major nutrients, glucose and glutamine, are often observed in tumors and cancer cell lines (reviewed in Baggetto, 1992; Gatenby and Gillies, 2004; Medina, 2001). Pathways of glucose and glutamine metabolism fuel processes vital for cellular proliferation and survival and can be controlled by several oncogenes involved in human cancers. For example, the MYC proto-oncogene regulates the expression of several enzymes of glycolysis, the Krebs cycle, mitochondrial respiration, and nucleotide synthesis (http://www.myccancergene.org/), as well as glutamine transporters and glutaminase (Gao et al., 2009; Wise et al., 2008), the first enzyme of glutamine catabolism; hepatocyte growth factor (HGF)/scatter factor and its tyrosine kinase receptor MET regulate carbohydrate metabolism (Kaplan et al., 2000; Perdomo et al., 2008); PI3K/AKT and RAS/MAPK signaling pathways, which are initiated by HGF binding to MET (Vogelstein and Kinzler, 2004), are well-known regulators of cellular metabolism (reviewed in (Yuneva, 2008); β-catenin, a central player in the Wnt pathway (Klaus and Birchmeier, 2008), regulates genes responsible for glutamine synthesis (Cadoret et al., 2002); and β-catenin activation in mouse liver is associated with altered expression of proteins regulating glycolysis and mitochondrial activity (Chafey et al., 2009). These reports provide important clues to understanding how expression of oncogenes promotes metabolic changes and indicate that such changes might vary among tumors carrying distinct oncogenic lesions. However, most of these studies were either performed in cell lines or were limited mainly to evaluating protein expression profiles that do not necessarily reflect the activity of metabolic pathways.

In this study, we used stable isotope-based metabolic analysis to evaluate how glucose and glutamine metabolism is altered during tumorigenesis initiated by individual oncogenes in vivo. We also assessed the expression and activity of the main enzymes regulating the metabolism of these two nutrients. In order to compare the effect of two distinct oncogenes, we used well-characterized mouse models of liver cancer induced by tissue-specific overexpression of either human MYC (Shachaf et al., 2004) or MET (Wang et al., 2001). Mouse liver tumors induced by MYC resemble immature hepatoblastomas with high mitotic activity (Shachaf et al., 2004; Tward et al., 2005), whereas tumors induced by MET resemble differentiated human hepatocellular carcinomas (HCCs) (Tward et al., 2005; Wang et al., 2001). The tumors induced by MET carry spontaneous activating mutations of β-catenin (Tward et al., 2007). Abnormal expression and activity of MYC (Kaposi-Novak et al., 2009; Thorgeirsson and Grisham, 2002), activating mutations and increased expression of MET (Kaposi-Novak et al., 2006; Ueki et al., 1997), and activating mutations of β-catenin (de La Coste et al., 1998; Tward et al., 2007) occur frequently in human liver cancers.
To evaluate whether the effect of oncogenic transformation on metabolism depends on the tissue context, we used a model of lung cancer induced by overexpression of MYC (Allen et al., 2011). Increased expression of MYC family members is observed in some human lung cancers (Gazzeri et al., 1994; Yokota et al., 1988), and MYC overexpression in the lungs of mice causes adenocarcinomas (Allen et al., 2011; Tran et al., 2008).

We found that glucose and glutamine metabolism in tumors varies with both the nature of the initiating lesion (MYC or MET) and the tissue of origin. Moreover, inhibition of Gls1, an isoform of glutaminase overexpressed in MYC-induced tumors, causes apoptosis in cells that have high levels of MYC and use glutamine to fuel the Krebs cycle. We conclude that metabolic profiling will be essential to determine the nature of metabolic alterations in tumors and to choose proper therapeutics aimed at these alterations.

**RESULTS**

**MYC and MET Have Different Effects on Glucose Metabolism in the Liver**

One of the hallmarks of cancer is aerobic glycolysis (the Warburg effect) associated with increased consumption of glucose and increased levels of lactate, a product of glucose catabolism (Warburg, 1956). Therefore, we first examined whether glucose metabolism was changed in mouse tumors induced by either MYC or MET transgenes expressed specifically in the liver of FVB/N mice under the control of a Tet-repressible promoter (Shachaf et al., 2004; Wang et al., 2001). Expression of the transgenes and tumor formation were induced by the removal of doxycycline from a diet. Transgenic animals kept on a doxycycline diet and wild-type FVB/N mice were used as controls.

We found that the levels of glucose were below normal in tumors induced by either MYC or MET (Figure 1A). Consistent with this, the expression of glucose-6-phosphatase, one of the key enzymes of glucose biosynthesis, was decreased in both...
types of tumors (see Figures S1A and S1B available online), suggesting that glucose synthesis might be deficient in both types of tumors. In MYC-induced tumors, decreased levels of glucose were frequently associated with increased levels of lactate in comparison with normal liver (Figure 1B). Moreover, lactate levels in MYC-induced tumors were significantly higher than in the ostensibly normal liver tissue adjacent to tumors (Figures S1C and S1D). Although in three out of seven MET-induced tumors we observed levels of lactate higher than in the adjacent tissue (data not shown), overall, MET-induced tumors did not demonstrate a statistically significant increase of lactate levels in comparison with either normal liver (Figure 1B) or adjacent liver tissue (Figures S1C and S1D).

In order to test if glucose catabolism contributes to increased lactate levels in MYC-induced tumors, we administered uniformly labeled [13C]-glucose, [U-13C]-glucose, to tumor-bearing animals. Administration of [U-13C]-glucose resulted in increase of 13C-lactate levels in liver tumors induced by MYC (Figures 1D and 1E and Figure 4C). In contrast, MET-induced tumors displayed only slight or no increase in 13C-lactate levels, which overall was not statistically significant (Figures 1C and 1E and Figure 4C). These results indicate that increased lactate levels in MYC-induced tumors may be, at least in part, the result of increased lactate production from glucose.

Lactate is produced from pyruvate, the end product of glucose catabolism through glycolysis, by lactate dehydrogenase (LDH), although the levels of LDH were increased only in MYC-induced tumors (Figure 1F), the levels of Ldha protein (Figure 1G) and total LDH activity (Figure 1H) were increased to the same extent in both types of tumors. This demonstrates that increased LDH activity is not the only factor responsible for the difference in lactate levels between tumors induced by the two onco genes.

To understand why increased LDH activity was accompanied by higher levels of glucose-derived lactate in MYC-induced tumors than in MET-induced tumors, we compared glucose transport and catabolism in both types of tumors. To analyze glucose transport, we used 18F-fluorodeoxyglucose (FDG) and positron emission tomography/computed tomography (PET/CT). Although glucose transport was above normal in both types of tumors, the intensity of FDG uptake was significantly higher in MYC-induced tumors than in MET-induced tumors (Figures 2A and 2B). The significantly higher glucose transport and comparably lower glucose levels in MYC-induced tumors suggest that these tumors catabolize glucose faster than MET-induced tumors.

We next compared the regulation of the first step of glucose catabolism, glucose phosphorylation, in the two types of tumors. In normal hepatocytes, glucose phosphorylation is catalyzed by glucokinase, which has a high Km (low affinity) for glucose and, in its active form, is localized in the cytosol (Bustamante et al., 2005). We found that glucokinase expression was decreased in MYC-induced tumors (Figures 2C and 2D). Consistent with
this, we detected glucose-6-phosphorylating activity with a high $K_m$ (17 mM) in the cytosolic fraction of normal liver but not in the cytosolic fraction of MYC-induced tumors (Table S1). In contrast to MYC-induced tumors, decreased expression of glucokinase in MET-induced tumors (Figures 2C and 2D) was associated with the emergence of glucose-6-phosphorylating activity in the cytosolic fraction of these tumors that had both decreased $K_m$ and $V_{max}$ compared to normal liver (Table S1). These results suggest that, although MET-induced tumors may have less glucokinase in comparison with normal liver, it may be a more efficient form of glucokinase.

Hexokinase II (Hk2) is a hexokinase isofrom that has a low $K_m$ (high affinity) for glucose and can be overexpressed in human tumors and cancer cell lines (Bustamante et al., 1981). Hk2 localizes both in the cytosol and at the mitochondrial membrane. Mitochondrial localization of Hk2 may increase its efficiency (Bustamante et al., 1981). We found that Hk2 expression was significantly increased in tumors induced by MYC but not in those induced by MET (Figures 2E and 2F). Consistent with this, glucose-6-phosphorylating activity with a low $K_m$ (0.01–0.08 mM) appeared in the mitochondrial fraction and increased 10-fold in the cytosolic fraction of MYC-induced tumors, while staying unchanged in MET-induced tumors (Table S1).

In addition to Hk2, tumors induced by MYC, but not MET, had increased expression of liver- and platelet-specific subunits of phosphofructokinase (Figure S2), one of the key glycolytic enzymes. Higher abundance of these subunits in the holoenzyme contributes to acceleration of glucose catabolism (Vora et al., 1985).

Altogether our results suggest that glucose transport and catabolism may be increased in both types of tumors in comparison with normal liver. However, MYC-induced liver tumors have significantly higher glucose uptake and catabolism than MET-induced liver tumors, which may explain why MYC-induced tumors have significantly increased levels of lactate whereas MET-induced tumors do not.

**MYC and MET Differently Affect Glutamine Metabolism in the Liver**

Glutamine is another major nutrient whose metabolism can be altered during tumorigenesis (Marquez et al., 1989). Nuclear magnetic resonance (NMR) analysis revealed that glutamine levels were undetectable in MYC-induced tumors (Figure 3A), whereas glutamine levels increased almost 2-fold in MET-induced tumors compared to normal liver (Figures 3B and 3C).

To reconcile the differences in the levels of glutamine between tumors induced by the two oncogenes, we evaluated the expression of two enzymes: glutamine synthetase (GluL), which catalyzes the ligation of ammonia and glutamate to produce glutamine, and phosphate-dependent glutaminase, which is responsible for glutamine catabolism into glutamate. Liver-type glutaminase (Gls2) is expressed in adult periporal hepatocytes, brain, and pancreas, whereas kidney-type glutaminase (Gls1) is expressed in embryonic hepatocytes, in most adult tissues with the exception of the postnatal liver, and in some cancer cell lines (Curthos and Watford, 1995; Perez-Gomez et al., 2005). We found that in MYC-induced tumors the expression of GluL was suppressed in comparison with normal liver (Figure 3D and Figure S3A), and the expression of the Gls2 isoform of glutaminase was replaced by the Gls1 isoform (Figures 3D and 3E and Figure S3B). Importantly, the shift in glutaminase isoforms was associated with an increase in glutaminase activity (Figure 3F).

Finally, MYC-induced tumors exhibited increased expression of the high-affinity glutamine transporter Slc1a5 (Figure 3D and Figure S3C), which is thought to supply cancer cell lines with amounts of glutamine sufficient for its increased catabolism (Bode, 2001). These results indicate that glutamine synthesis is decreased in MYC-induced tumors, whereas its transport and catabolism are increased.

In contrast to MYC-induced tumors, MET-induced tumors had increased expression of Glul (Figure 3D and Figure S3A), which was consistent with the presence of activating mutations in β-catenin (Tward et al., 2007), a transcriptional activator for Glul (Cadoret et al., 2002). Moreover, in MET-induced tumors Gls2 expression was decreased (Figure 3D and Figure S3B), Gls1 was not expressed (Figures 3D and 3E), and the expression of Slc1a5 was only slightly higher than normal (Figure 3D and Figure S3C). Consistent with the expression pattern of glutamine-metabolizing enzymes, administration of uniformly labeled $^{13}$C-glutamine, $[^{13}$C]-glutamine, to tumor-bearing mice resulted in significant buildup of $^{13}$C-glutamine in MET-induced tumors (Figure 4D, right panel), indicating that glutamine was transported into tumors, but its catabolism was significantly decreased in comparison with normal liver.

One of the main substrates for glutamine biosynthesis is glucose. Administration of $[^{13}$C]-glucose resulted in increased levels of $^{13}$C-glutamine in MET-induced tumors (Figure 3G and Figure 4C, left panel). Together these results indicate that in MET-induced tumors, increased consumption of glucose contributes to increased glutamine biosynthesis, and the elevated levels of glutamine could result from both increased synthesis and repressed catabolism. We conclude that glutamine catabolism is increased in MYC-induced tumors, whereas glutamine production is increased in MET-induced tumors.

**MYC-Induced Tumors Have Increased Synthesis of Krebs Cycle Intermediates**

Since glucose and glutamine are the main fuels of the Krebs cycle, we compared total levels of the Krebs cycle intermediates (fumarate, malate, and citrate) and related metabolites (glutamate and aspartate) in the two types of tumors and normal liver. The levels of all these compounds were increased in MYC-induced but not in MET-induced tumors (Figures 3A and 3B and Figures 4A and 4B). Moreover, administration of either $[^{13}$C]-glucose or $[^{13}$C]-glutamine resulted in increased levels of $^{13}$C-citrate, $^{13}$C-glutamate, and $^{13}$C-aspartate in MYC-induced tumors (Figures 4C and 4D, Figures 4A and 4B). This contrasted with MET-induced tumors, which displayed either insignificant or no changes (Figures 4C and 4D, Figures 4A and 4B). These results suggest that increased transport and catabolism of both glucose and glutamine in MYC-induced tumors contribute to the synthesis of Krebs cycle intermediates, which is significantly enhanced in comparison with normal liver and MET-induced tumors.

Injection of $[^{13}$C]-glutamine also resulted in increased incorporation of $^{13}$C into lactate in MYC-induced tumors (Figure 4D, right panel), indicating that increased catabolism of glutamine...
Figure 3. Glutamine Metabolism Is Different in Liver Tumors Induced by Either MYC or MET

(A and B) Glutamine levels determined by NMR in tumors and normal livers from transgenic mice kept on doxycycline. Representative 1H NMR profiles of normal livers and tumors are shown (at least four animals per group). Glutamine peaks are in 2.42–2.47 ppm region, and glutamate peaks are in 2.32–2.37 ppm region. The profiles were normalized to the initial dry weight.

(C) Glutamine concentration quantified in normal livers and MET-induced tumors based on 1H-NMR data in (B).

(D) Expression of indicated proteins evaluated by immunoblotting of whole-tissue lysates using β-actin as a loading control.

(E) Gls1 RNA levels measured in normal and tumor tissues using mouse β-actin as an internal control.

(F) Phosphate-dependent glutaminase activity measured in the mitochondrial fraction of MYC-induced tumors and normal livers from transgenic mice kept on doxycycline. All values are given as the mean ±SD.

(G) Detection of 13C-labeled glutamine by 1H-13C heteronuclear single quantum coherence spectroscopy (HSQC) NMR performed on extracts of tumor-adjacent and tumor tissues from animals injected with [U-13C]glucose (5 animals per group). The representative HSQC spectra are shown. 13C-4-glutamine peak is at 2.45 ppm. Consistent with glutamine depletion, a corresponding 13C-4-glutamine peak was not observed in MYC-induced tumors. The profiles were normalized to the initial dry weight of tissue. See also Figure S3.
may contribute to the increased lactate levels observed in these tumors. However, currently we cannot discern whether labeled lactate was produced from glutamine through glutaminolysis (DeBerardinis et al., 2008) or was the result of increased catabolism of glucose that was derived from [U-\(^{13}\)C]-glutamine through gluconeogenesis.

Figure 4. Catabolism of Glucose and Glutamine Contributes to Increased Synthesis of Krebs Cycle Intermediates in MYC-Induced Liver Tumors

(A and B) The levels of Krebs cycle intermediates measured in tissue extracts by GC-MS. Values are given as the mean ± SD.

(C and D) The representative spectra of \(^1\)H-\(^{13}\)C HSQC NMR performed on extracts of tumor-adjacent and tumor tissues from animals injected with either [U-\(^{13}\)C]-glucose (C) or [U-\(^{13}\)C]-glutamine (D) (at least three animals per group). The profiles were normalized to the initial dry weight. Glc, glucose; G6P, glucose-6-phosphate; Glu, glutamate; GSH, reduced glutathione; GSSG, oxidized glutathione; Gin, glutamine; Asp, aspartate; Suc, succinate; Ala, alanine; Lac, lactate. See also Figure S4.
To evaluate if metabolic changes induced by oncogenic transformation are tissue specific, we analyzed the main pathways of glucose and glutamine metabolism in lung adenocarcinomas induced by MYC (Allen et al., 2011). Expression of MYC was driven specifically in pneumocytes of FVBN mice by a Tet-activated promoter by keeping mice on a doxycycline diet (Allen et al., 2011; Tran et al., 2008). Normal lungs from wild-type mice and mice fed a diet without doxycycline were used as controls. We found that the levels of lactate (Figure 5A) as well as expression of both Hk2 and Ldha (Figure 5B) were increased in lung tumors induced by MYC. This suggested that, similar to liver tumors, MYC-induced transformation was associated with increased glucose catabolism into lactate in lung tumors. In contrast to liver tumors, however, lung tumors induced by MYC had elevated levels of glutamine (Figure 5C).

Although expression of Gls1 was increased in MYC-induced lung tumors, expression of Glul also appeared to be above normal in three out of four lung tumors (Figure 5D). Immunohistochemical analysis revealed that in normal lungs Glul expression was restricted to bronchial epithelium (Figure 5E), whereas in lung tumors Glul was highly expressed in tumor cells (Figures 5F–5H). The expression of Gls2 in normal lungs was lower than in the liver and did not change in lung tumors (Figure 6A and data not shown). By analogy with previous experiments conducted on human lung cancer patients infused with [U-13C]-glucose (Fan et al., 2009), increased glutamine production in MYC-induced mouse lung tumors might be the result of increased glucose conversion into glutamine. Although glutamine catabolism may also be increased in lung tumors due to the increased Gls1 expression, increased Glul expression could override increased Gls1 expression and account for increased net glutamine levels.

Tissue Context Affects the Outcome of Metabolic Reprogramming by MYC

To evaluate if metabolic changes induced by oncogenic transformation are tissue specific, we analyzed the main pathways of glucose and glutamine metabolism in lung adenocarcinomas induced by MYC (Allen et al., 2011). Expression of MYC was driven specifically in pneumocytes of FVBN mice by a Tet-activated promoter by keeping mice on a doxycycline diet (Allen et al., 2011; Tran et al., 2008). Normal lungs from wild-type mice and mice fed a diet without doxycycline were used as controls.

We found that the levels of lactate (Figure 5A) as well as expression of both Hk2 and Ldha (Figure 5B) were increased in lung tumors induced by MYC. This suggested that, similar to liver tumors, MYC-induced transformation was associated with increased glucose catabolism into lactate in lung tumors. In contrast to liver tumors, however, lung tumors induced by MYC had elevated levels of glutamine (Figure 5C).

Although expression of Gls1 was increased in MYC-induced lung tumors, expression of Glul also appeared to be above normal in three out of four lung tumors (Figure 5D). Immunohistochemical analysis revealed that in normal lungs Glul expression was restricted to bronchial epithelium (Figure 5E), whereas in lung tumors Glul was highly expressed in tumor cells (Figures 5F–5H). The expression of Gls2 in normal lungs was lower than in the liver and did not change in lung tumors (Figure 6A and data not shown). By analogy with previous experiments conducted on human lung cancer patients infused with [U-13C]-glucose (Fan et al., 2009), increased glutamine production in MYC-induced mouse lung tumors might be the result of increased glucose conversion into glutamine. Although glutamine catabolism may also be increased in lung tumors due to the increased Gls1 expression, increased Glul expression could override increased Gls1 expression and account for increased net glutamine levels.

Increased levels of Glul protein and glutamine were also observed in ostensibly normal lung tissue adjacent to mouse tumors (Figures 5C and 5D). Immunohistochemical analysis showed that Glul was expressed in immune cells infiltrating the normal tissue (Figure 5I), which could account at least in part for the increased levels of Glul and glutamine.

Together these data demonstrate that, although some mechanisms that regulate metabolic pathways in MYC-induced liver tumors are similarly altered in MYC-induced lung tumors, tissue-specific differences in the outcome do exist.

**MYC Sensitizes Cells to Inhibition of Glutaminase**

We have previously demonstrated that glutamine metabolism through the Krebs cycle is required for the survival of cells that overexpress MYC (Yuneva et al., 2007). Since the shift from Gls2 to Gls1 accompanies the increase in glutamine catabolism...
through the Krebs cycle in MYC-induced mouse liver tumors (Figure 3D and Figure 4D), we reasoned that Gls1 could be a plausible target for eliminating cells that catabolize glutamine and overexpress MYC. To test this possibility, we used normal human lung fibroblasts (IMR90) and immortalized human kidney epithelial cells (HA1E) expressing conditional versions of MYC.

Figure 6. GLS1 Inhibitors Affect Glutamine Catabolism through the Krebs Cycle

(A) IMR90-ERMYC and HA1E-MYCER cells were incubated for 24 hr with either OHT (MYC On) or 0.1% ethanol (MYC Off). Expression of GLUL, GLS2, and GLS1 was detected in whole lysates of these cells, normal liver and lung as well as of MYC-induced liver and lung tumors by immunoblotting using β-actin as a loading control. Asterisk indicates crossreactive band recognized by anti-Gls2 antibody in human cell lines.

(B and C) IMR90-ERMYC cells with induced MYC activity were incubated with 2 mM [U-13C]-glutamine and indicated concentrations of BPTES for 12 hr. DMSO (0.1%) was used as a vehicle control. Absolute concentrations (B) and 13C isotopologue enrichment (C) of indicated compounds were measured by GC-MS. In (C), metabolite+0 represents monoisotopic or unlabeled isotopologue, while metabolite+1–5 are isotopologues with one to five 13C atoms. The results were referenced to the initial dry weight of cell pellet. An average of two replicate samples is presented. The experiment was repeated twice.

(D) IMR90-ERMYC cells with induced MYC were incubated with 2 mM 15N2-glutamine and indicated concentrations of BPTES, 20767, or DON. Incorporation of 15N into adenine nucleotides (AXP) was evaluated by 1H NMR. The profiles are referenced to the dry weight of cell pellet and the internal standard concentration. The representative profiles from two independent experiments are presented. See also Figures S5 and S6.
Determinants of Tumor Metabolism In Vivo

(IMR90-ERMYC and HA1E-MYCC) that can be activated by 4-hydroxytamoxifen (OHT) (Yuneva et al., 2007), as well as HA1E cells that constitutively overexpress wild-type MYC (HA1E-MYCC). We found that all of these lines had metabolic features resembling those of MYC-induced liver tumors, irrespective of the presence or absence of active ectopic MYC, namely (1) levels of GLS1 comparable to those in the tumors (Figure 6A and Figure 7D), (2) prevalence of GLS1 over GLS2 expression (Figure 6A), and (3) low levels of GLS2 and GLUL (Figure 6A). Moreover, all of the cell lines had glucose as the primary source of lactate (Figures S5A and S5C, and data not shown) and glutamine as the principal fuel for the Krebs cycle (Figures S5B and S5D and data not shown). We attribute this phenotype to the relative abundance of endogenous MYC in the cell lines (Figure 7D and data not shown), which could represent adaptation to sustained propagation in vitro. It remains the case, however, that a further increase in MYC activity increases the sensitivity of HA1E and IMR90 cells to glutamine deprivation (Yuneva et al., 2007). These results indicate that different levels of MYC might be required to change a metabolic phenotype of the cells and to make them dependent on glutamine for survival. We proceeded to test the response of IMR90 and HA1E cells to inhibition of GLS1 in the absence and presence of augmented MYC activity.

We used an inhibitor of GLS1, bis-2-(5-phenylacetoamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) (Robinson et al., 2007), and its water-soluble analog, 20767 (Erdmann et al., 2007). Together with increasing the levels of glutamate, both BPTES and 20767 decreased the levels of glutamate and other Krebs cycle intermediates and their products (Figure 6B, Figure 6A, and data not shown), as well as the incorporation of glutamate-derived 13C into these compounds (Figure 6C, Figure S6B, and data not shown) in IMR90-ERMYC cells incubated either with or without OHT. Importantly, unlike 6-diazo-5-oxo-L-norleucine (DON), a glutamine analog and inhibitor of both glutaminase and amidotransferases, neither BPTES nor 20767 inhibited the incorporation of glutamine-derived 15N into adenine nucleotide species (Figure 6D). These results indicate that both BPTES and 20767 inhibit glutaminase activity but spare amidotransferase activities involved in nucleotide biosynthesis.

Both BPTES and 20767 induced apoptosis in IMR90-ERMYC and HA1E-MYCC cells in a MYC-dependent manner (Figure 7A). Moreover, HA1E-MYCC cells were more sensitive to BPTES treatment than HA1E transduced with a vector control (HA1E-Vector) (Figure 7B). Silencing GLS1 expression by two independent shRNAs in HA1E-MYCC and HA1E-Vector cells confirmed that the BPTES effect on the viability of cells with ectopically expressed MYC was due to inhibition of GLS1 activity (Figure 7C). Treatment with 20767 also killed human Burkitt’s lymphoma cell lines that overexpress MYC as a consequence of well-characterized translocations of MYC (Figure 7E). In contrast to MYC, ectopic expression of H-RASV12 did not sensitize HA1E cells to either glutamine deprivation or inhibition of GLS1 activity (Figures 7B and 7C).

We conclude that MYC but not H-RASV12 exhibits a synthetic lethal interaction with the inhibition of GLS1 activity and that overexpression of MYC may be a valuable biomarker for sensitivity to such inhibition. Moreover, specific inhibition of glutaminase might be less toxic than a therapy employing glutamine analogs that may interfere with nucleotide biosynthesis and thus induce DNA damage (Hastak et al., 2008).

DISCUSSION

Determinants of Tumor Metabolism

Here we demonstrate that liver tumors induced by either MYC or MET have distinct metabolic phenotypes. Moreover, the metabolism of MYC-induced liver tumors differs from the metabolism of MYC-induced lung tumors. Some of the metabolic changes that are observed during MYC-induced tumorigenesis in both liver and lung, including increased expression of Hk2, Ldha, and Gls1, may be the result of MYC overexpression itself (Gao et al., 2009; Osthus et al., 2000; Wise et al., 2008). On the other hand, there are differences between liver and lung tumors induced by MYC that may be due to other tumorigenic events or determined by tissue-specific functions. For example, MYC-induced lung tumors are distinguished from those in the liver by increased expression of Glul. Whereas, to the best of our knowledge, regulation of Glul expression by MYC has never been reported, Glul is a well-known transcriptional target of β-catenin (Cadoret et al., 2002), which is activated in a subset of human lung cancers (Sunaga et al., 2001). However, our immunohistochemical analysis revealed that in MYC-induced lung tumors, β-catenin is located at the cytoplasmic membrane rather than in the nucleus (data not shown), indicating that the protein had not been activated by mutation and is not likely the cause of Glul overexpression. During inflammation, expression of Glul can be stimulated by glucocorticoids in lung epithelial cells (Abcouver et al., 1996). This suggests that increased Glul expression in MYC-induced lung tumor cells may be induced by tumor-associated inflammation.

Although in liver tumors the expression of both Gls1 and Glul is regulated at the RNA level (Figure 3 and Figure S3A), the expression of these proteins in lung tumors is regulated at the protein level (data not shown). This observation is consistent with the ability of MYC to regulate protein expression posttranscriptionally (Chang et al., 2008) and with variations in the regulation of Gls1 expression by MYC among cell lines of different origin (Gao et al., 2009; Wise et al., 2008). It also suggests that the mechanism of regulation of metabolic enzyme expression either by MYC or other factors involved in tumorigenesis is context specific.

Increased Lactate Levels and LDH Activity Do Not Always Correlate in Tumors

Increase in glucose consumption and lactate production even in the presence of normal oxygenation is a widely recognized characteristic of tumor metabolism. Our results show that, although the activity of LDH, the enzyme responsible for pyruvate conversion into lactate, was increased to the same extent in liver tumors induced by either MYC or MET (Figure 1H), a significant increase in lactate levels was only observed in MYC-induced tumors (Figure 1B and Figure S1C). This demonstrates that increased LDH activity does not necessarily correlate with increased lactate levels in tumors.

In both MYC- and MET-induced liver tumors, the activities of glucose transport and glucose phosphorylation were higher than in normal liver (Figure 2 and Table S1), indicating that...
Figure 7. GLS1 Inhibitors Induce MYC-Dependent Apoptosis

(A) MYC activity was induced in HA1E-MYCER and IMR90-ERMYC cells as described in Figure 6A. Cells then were treated with indicated concentrations of BPTES or 20767 or with 5 mM DON. DMSO (0.1%) was used as a vehicle control for the experiments with BPTES. HA1E-MYCER cells were treated for 36 hr, and IMR90-ERMYC cells were treated for 48 hr and the percentage of apoptotic nuclei was scored. The average of three independent experiments is presented ±SD.

(B) Vector, MYC, and RASV12 cells were treated with indicated concentrations of BPTES or 20767 or with 5 mM DON. DMSO (0.1%) was used as a vehicle control for the experiments with BPTES. The percentage of apoptotic nuclei was scored. The average of three independent experiments ±SD is shown.

(C) Cells were treated with indicated concentrations of BPTES or 20767 or with 5 mM DON. DMSO (0.1%) was used as a vehicle control for the experiments with BPTES. The percentage of apoptotic nuclei was scored. The average of three independent experiments ±SD is shown.

(D) Western blots showing the expression levels of MYC, RAS, P-ERK, ERK, and actin in HA1E-Vector, HA1E-MYC, HA1E-RASV12, F/BIN, and MYC-Tumor cells.

(E) Kaplan-Meier plots showing the percentage of Annexin V and PI positive cells in HL60, DAUDI, and RAMOS cells treated with DMSO or 150 μM 20767 for 0, 12, 24, 36, and 48 hours.

Figure 7. GLS1 Inhibitors Induce MYC-Dependent Apoptosis

(A) MYC activity was induced in HA1E-MYCER and IMR90-ERMYC cells as described in Figure 6A. Cells then were treated with indicated concentrations of BPTES or 20767 or with 5 mM DON. DMSO (0.1%) was used as a vehicle control for the experiments with BPTES. HA1E-MYCER cells were treated for 36 hr, and IMR90-ERMYC cells were treated for 48 hr and the percentage of apoptotic nuclei was scored. The average of three independent experiments is presented ±SD.
NAD+ required for the turnover of glycolysis. The increased expression of LDH serves to ensure that once any surplus of pyruvate becomes available, it is efficiently converted into lactate regenerating NAD⁺ required for the turnover of glycolysis (Spriet et al., 2000). Moreover, increased glutamine catabolism observed in MYC-induced tumors may also contribute to creating a surplus of pyruvate available to LDH (DeBerardinis et al., 2008); and MYC and MET may have different effects on the activity of pyruvate-utilizing enzymes that compete with LDH, as well as the redox state of the cells. Nevertheless, increased expression of LDH in MET-induced tumors may serve to ensure that once any surplus of pyruvate becomes available, it is efficiently converted into lactate regenerating NAD⁺ required for the turnover of glycolysis. The increased expression of LDH observed in either MYC or MET-induced tumors may also play a role independent of its metabolic function (Ronai, 1993).

**The Role of Metabolic Changes in MYC- and MET-Induced Tumorigenesis**

The combination of glucose catabolism into lactate and glutamine catabolism through the Krebs cycle was suggested to support rapid proliferation of tumor cells by simultaneously supplying them with ATP and biosynthetic precursors (DeBerardinis et al., 2008; McKeehan, 1982). Indeed, MYC-induced liver tumors, which have increased lactate production from glucose and increased catabolism of both glucose and glutamine through the Krebs cycle, demonstrate higher proliferation than MET-induced liver tumors (Figure S7A), which do not significantly increase glucose catabolism into lactate and produce rather than catabolize glutamine.

Elevated intracellular levels of glutamine were proposed to prime cells for activation of the mammalian target of rapamycin complex 1 (mTORC1), one of the major regulators of cell growth and proliferation (Nicklin et al., 2009). Thus, increased GLUL expression and the resulting elevated intracellular glutamine levels in MET-induced liver tumors and MYC-induced lung tumors might serve to ensure mTORC1 activity in the absence of exogenous glutamine and give tumor cells an advantage in nutrient-restricted conditions. Consistent with this hypothesis, glutamine deprivation did not affect phosphorylation of S6 (P-S6), a marker of mTORC1 activity, in Huh7 or HEPG2 cells, which have high levels of GLUL (Figure S7B). In contrast, glutamine deprivation caused a reduction of P-S6 in SK-HEP-1 cells, which do not have detectable GLUL expression (Figure S7B).

**Synthetic Lethal Interaction between MYC and Inhibition of GLS1**

Our present work demonstrates that inhibitors of Gls1 might eliminate tumor cells that overexpress MYC and catabolize glutamine to feed the Krebs cycle. In most of the MYC-induced lung tumors we examined, however, increased expression of Gls1 was accompanied by increased expression of Glul (Figure 5), which indicates that these tumors may both catabolize and produce glutamine. Increased expression of Glul can be sufficient to protect cells from glutamine deprivation (Kung et al., 2011). However, whether it can render cells that overexpress MYC resistant to GLS1 inhibition remains to be investigated. The contribution of various anaplerotic pathways that can contribute to the Krebs cycle (Cheng et al., 2011) should also be taken into account when identifying malignancies that might benefit from inhibiting glutaminase activity.

Since the GLS2 isoform of glutaminase is responsible for glutamine catabolism in normal liver, selective inhibition of GLS1 offers an opportunity to target glutamine catabolism of liver tumors that overexpress MYC without affecting the metabolism of normal liver. On the other hand, GLS1 inhibition may be toxic to other normal tissues that express GLS1, such as kidney, intestine, lung, and brain. However, our results demonstrate that expression of GLS1 in IMR90 and HA1E cells does not expose the cells to the lethal effect of GLS1 inhibition unless high levels of MYC are present, indicating that normal tissues with normal MYC levels may not be affected by GLS1 inhibitors. One of the well-known consequences of MYC overexpression is the induction of apoptosis by shifting the balance between prosurvival and prodeath signals (Meyer and Penn, 2008). The reduction in the Krebs cycle activity in response to GLS1 inhibition (Figure 6 and Figure S6) may represent a stress signal that can unleash the proapoptotic activity of MYC when the gene is expressed above a certain threshold (Murphy et al., 2008).

Glutamine is a substrate for multiple metabolic reactions, and glutaminase catalyzes only one of them. Indeed, complete deprovision of glutamine is more efficient in killing cells with high levels of MYC than inhibition of glutaminase (Figure 7B). This suggests that other pathways of glutamine metabolism may provide the opportunity for additional synthetic lethal interactions with the overexpression of MYC (DeBerardinis and Cheng, 2010; Mates et al., 2006). Identification of such interactions might provide additional therapeutic opportunities.

(B) HA1E cells transduced with either empty vector or vectors carrying either MYC or H-RASV12 were either incubated in glutamine-free media or treated with indicated concentrations of BPTES for 24 hr. Apoptosis was scored in three independent replicate samples. The values are given as the mean ±SD. A representative of two independent experiments is shown.

(C) HA1E-derived cell lines were infected with lentiviruses expressing either a scrambled shRNA (shScr) or two independent shRNAs targeting GLS1 (shGLS1_1 and shGLS1_2). Cells were collected 36 or 48 hr after the infection, GLS1 expression was evaluated by immunoblotting, and apoptosis was scored by counting apoptotic nuclei. For each shRNA the experiment was repeated at least twice. Transduction with empty pLKO.1 vector (EV) was used to account for the exceptional level of cell death induced by lentiviral infection observed specifically in HA1E cells with ectopic expression of MYC.

(D) The ectopic expression of MYC and H-RASV12, as well as expression of ERK, P-ERK, and GLS1, was estimated by western blotting in whole-cell lysates. Increased expression of P-ERK indicates increased activity of RAS.

(E) Indicated Burkitt's lymphoma cell lines were cultured in the presence of 150 μM 20767. Cell death was analyzed by Annexin V and PI staining. A representative of two independent experiments is shown.
**EXPERIMENTAL PROCEDURES**

**Animals**

Oncogene-driven liver (Shachaf et al., 2004; Wang et al., 2001) and lung (Allen et al., 2011; Tran et al., 2008) tumors were generated as described previously. See the Supplemental Experimental Procedures for more details.

For isotopomer analysis of either glucose or glutamine metabolism, tumor-bearing mice were injected with either 20 mg of [U-13C]-glucose (Cambridge Isotope Laboratories) (Fan et al., 2011) or with three consecutive injections (with a 15 min interval) of [U-13C]-glutamine, 7 mg each (Cambridge Isotope Laboratories) i.v. Mice were sacrificed 15 min after the last injection. The percent of 13C enrichment in either glucose or glutamine was comparable between tumor-free liver tissue and tumors from animals with either MYC or MET-induced liver tumors. The percent of 13C enrichment in glutamine varied between 13% and 42% depending on an individual animal. Samples of tumor and adjacent liver tissue were snap frozen in liquid nitrogen. All experiments were performed according to protocols approved by the Committee on Animal Research at the University of California, San Francisco.

**Cell Culture**

Primary IMR90 human lung fibroblasts and immortalized H1E human kidney epithelial cells expressing ER-MYC or MYC-ER, respectively, were described previously (Yuneva at al., 2007). H1E1 cells with ectopic expression of MYC or H-RASV12 were generated by transduction with the retroviral vector pMaRX-puro (Hannon et al., 1999) carrying either MYC or H-RASV12 as described previously (Faliero and Laizebnik, 2000). See the Supplemental Experimental Procedures for the detailed description of culture, treatment conditions, and sequence of shRNAs.

**Metabolite Profiling**

All frozen tissue samples for metabolite analysis were pulverized and lyophilized. Frozen cell pellets were lyophilized. Metabolites were extracted and analyzed by NMR and gas chromatography-mass spectrometry (GC-MS) as described previously (Fan, 2010; Fan et al., 2009). See the Supplemental Experimental Procedures for more details.

**18F-FDG PET/CT Imaging**

The animal handling and preparation protocols followed established procedures to obtain consistent PET results (Fueger et al., 2006) (see the Supplemental Experimental Procedures for more details). For quantitative assessment, volumes of interest (VOIs) were placed in liver (cylinder having 5 mm diameter with 5 mm height) involving tumors when present, and in brain (cylinder having 3 mm diameter with 3 mm height) mostly involving cerebellum. The uptake in the liver VOI was normalized to the uptake in the brain VOI.

**Enzyme Assays**

A mitochondrial fraction was isolated from freshly excised normal livers or tumors as described previously (Frezza et al., 2007). Cytosol was further separated from microsomes by centrifugation at 103,000 g for 60 min. LDH activity was measured in the cytosolic fraction, glucose-6-phosphorylating activities were measured in cytosolic and mitochondrial fractions, and phosphate-dependent glutaminase activity was measured in mitochondrial fractions. See the Supplemental Experimental Procedures for more details.

**Quantitative PCR Analysis and Western Blotting**

Protocols, TaqMan Gene Expression Assays, and antibodies are described in the Supplemental Experimental Procedures.

**Statistical Analysis**

Statistical analysis was performed by applying a two-tailed Student’s t test. For the experiments in which concentration of total and 13C-labeled lactate and glutamate were compared in tumors and adjacent liver tissue (Figure 1E, Figures S1C and S4), paired Student’s t test was used. For all other analysis, unpaired Student’s t test was used.

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes seven figures, one table, Supplemental Experimental Procedures, and Supplemental References and can be found with this article online at doi:10.1016/j.cmet.2011.12.015.

**ACKNOWLEDGMENTS**

We thank Dr. A. Lane, Dr. S. Arumugam, J. Tan, and R. Burra (University of Louisville, Louisville, KY) for help with metabolic profiling analysis and Dr. A. Lane for valuable comments on the manuscript; Drs. A. Goga and A. Balakrishnan (University of California, San Francisco, San Francisco, CA) for useful discussion of preliminary results; L. Urisman (University of California, San Francisco, San Francisco, CA) for assistance with animal husbandry; and members of the Bishop Laboratory for valuable discussions and comments. NMR analyses were supported in part by National Institutes of Health (NIH) Grant P20RR018733 from the National Center for Research Resources and National Science Foundation (NSF) EPSCoR grant EPS-0447479. Metabolite profiling analysis was supported by NSF EPSCoR grant EPS-0447479, National Cancer Institute (NCI) grants 1R01CA118434-01A2 and 3R01 CA118434-0251; and University of Louisville CTSPGP award (T.W.M.F.). The work was also supported by UCSF/G.W. Hoover Research Foundation Endowment Funds and by NCI Grant R35 CA44338 (J.M.B.); by UCSF Hellen Diller Family Comprehensive Cancer Center Pilot Grant and the UCSF Department of Radiology and Biomedical Imaging Seed Grant 10-09 (K.C. and Y.S.); by the Johns Hopkins Brain Science Institute through the NeuroTranslational Program (T.T. and D.V.F.); by NIH Grant R21NS074151 (to T.T.); and by Ministerio de Ciencia y Tecnología SAF2010-17573 and Junta de Andalucía, Proyectos de Investigación de Excelencia, Convocatoria 2010, CVI-6656, Spain (J.M.M. and F.J.A.).

Received: January 25, 2011

Revised: August 1, 2011

Accepted: December 16, 2011

Published online: February 7, 2012

**REFERENCES**


